PIK3CA and cancer: This hypothesis is supported by the significant therapeutic activity of PI3K inhibitors on micrometastases and small tumour lesions.36 In order to identify some possible soluble mediators of such protective activity, we then measured the release of cytokines from cancer-associated fibroblasts (CAFs).